HomeBiosimilar Antibodies

Biosimilar Antibodies

Cat.No. Product Name Information Isotype
A2844 Anti-Clathrin Heavy Chain / CHC Anti-Clathrin Heavy Chain / CHC is a human monoclonal antibody against clathrin heavy chain (CHC) with potential anti-angiogenesis and anti-tumor activity. MW: 145.62 KD. Human IgG1
A3100 Ruplizumab (Anti-TNFSF5 / CD40L / CD154) Ruplizumab (Anti-TNFSF5 / CD40L / CD154) is a humanized monoclonal antibody targeting CD40L(TNF Receptor). It has the potential for systemic lupus erythematosus disease research. MW :145.68 KD. Human IgG1
A2845 Elsilimomab (Anti-IL-6 / IFNb2) Elsilimomab (Anti-IL-6 / IFNb2) is an IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab has the potential to be used in research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA). MW : 145.96 KD. Human IgG1
A3101 Vilobelimab (Anti-Complement C5) Vilobelimab (Anti-Complement C5) is a monoclonal antibody targeting C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. It may be used in studies related to sepsis, COVID-19, etc. MW :145.9 KD. Human IgG4SP
A2846 Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) Anti-TNFRSF5 / CD40 (Emory U. anti-CD40) is a monoclonal antibody against CD40 (also called TNFRSF5) with potential antitumor activity. MW: 143.74 KD. Human IgG1
A2847 Lendalizumab (Anti-Complement C5) Lendalizumab (Anti-Complement C5) is a proprietary antibody that targets the complement protein C5a with potential immunomodulating and anti-inflammatory activities. MW : 146.02 KD. Human IgG2SA
A3103 Anti-TrkB / NTRK2 Anti-TrkB / NTRK2 is an antibody targeting TrkB. It is used to improve nerve function, including treatment of peripheral neuropathies. MW :146.68 KD. Human IgG2SA
A2848 Enoticumab (Anti-DLL4) Enoticumab (Anti-DLL4) is a human monoclonal antibody directed against Delta-like ligand-4 (DLL4) with potential antineoplastic activity.It has been used to treat  advanced solid tumors MW : 146.48 KD. Human IgG1
A3105 Anti-TSPAN26 / CD37 (AGS67E) Anti-TSPAN26 / CD37 (AGS67E) is a fully human monoclonal antibody that targets CD37. It is used for the potential treatment of B/T-cell malignancies. MW :143.44 KD. Human IgG2SA
A3106 Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) is a monoclonal antibody targeting Integrin a5b1 (ITGA5 & ITGB1). It can be used in treatment of solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer. MW :145.52 KD. Human IgG4SP
A2851 Emactuzumab (Anti-CSF1R / M-CSFR / CD115) Emactuzumab (Anti-CSF1R / M-CSFR / CD115) is a humanized monoclonal antibody directed against the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R, CSF-1R, CD115), also known as macrophage colony-stimulating factor receptor (M-CSFR), with potential antineoplastic and immunomodulating activities MW : 146.94 KD. Human IgG1
A3107 Anti-VCAM1 / CD106 Anti-VCAM1 / CD106 is a conjugated liposome targeting vascular cell adhesion molecule (VCAM)-1. It serves as a drug delivery system with dual functions: targeted delivery and solubilizing capacity. MW :143.4 KD. Human IgG2SA
A2596 Tilvestamab (Anti-AXL / UFO) Tilvestamab (Anti-AXL / UFO) is a humanized antibody targeting AXL.Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas. MW :146.16 KD. Human IgG1
A2852 Anti-CSF1R / M-CSFR / CD115 (LY3022855) Anti-CSF1R / M-CSFR / CD115 (LY3022855) is a recombinant, immunoglobulin, human monoclonal antibody directed against colony stimulating factor 1 receptor (CSF1R) with potential antineoplastic activity. MW : 179.2 KD. Human IgG1
A3108 Varisacumab (Anti-VEGFA) Varisacumab (Anti-VEGFA) is a human recombinant monoclonal antibody targeting VEGFA. It may be used in research of Microvascular complications of diabetes 1 (MVCD1). MW :145.62 KD. Human IgG1
A2597 Alsevalimab (Anti-B7-H4 / VTCN1) Alsevalimab (Anti-B7-H4 / VTCN1) is a human monoclonal antibody targeting B7-H4. It has potential antineoplastic and immune checkpoint inhibitory activities. MW :144.74 KD. Human IgG1
A2853 Gimsilumab (Anti-CSF2 / GM-CSF) Gimsilumab (Anti-CSF2 / GM-CSF) is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the myeloid cell growth factor and inflammatory mediator granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential immunomodulating activity. MW : 145.8 KD. Human IgG1
A3109 Alacizumab (Anti-VEGFR2 / KDR / CD309) Alacizumab (Anti-VEGFR2 / KDR / CD309) is a humanized monoclonal antibody targeting VEGFR2 / KDR / CD309 . It has anti-tumour effect in tumour growth. MW :144.08 KD. Human IgG1
A2598 Anti-CLEC4C (BIIB059) Anti-CLEC4C (BIIB059) is a humanized IgG1-κ antibody targeting to C-type lectin domain family 4 member C (CLEC4C). It can be used for cutaneous lupus erythematosus (CLE) study. MW :146.34 KD. Human IgG1
A2854 Lenzilumab (Anti-CSF2 / GM-CSF) Lenzilumab (Anti-CSF2 / GM-CSF) is a recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. MW: 145.72 KD. Human IgG1